 Company selected for oral presentation on mucopolysaccharidosis-1 MPS-1, demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model Company selected for oral presentation on mucopolysaccharidosis-1 MPS-1, demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model 